• Facebook
  • Rss
  • Twitter
  • Youtube
  • Store
  • Donate
NCCS - National Coalition for Cancer Survivorship
  • About
    • Our Mission
    • Our History
    • Our Leadership
      • Policy Advisors
    • Employment
    • Partnerships
    • Financial Information
  • Policy
    • Quality Cancer Care
    • Access to Care
    • Health Equity
    • Redefining Functional Status (RFS)
    • 2020 State of Cancer Survivorship Survey
    • Cancer Care Planning and Communications Act (CCPCA)
  • Get Involved
    • What is Advocacy?
    • Cancer Policy and Advocacy Team (CPAT)
    • Elevating Survivorship
    • Survivor Stories
    • Cancerversary
    • State Based Cancer Advocacy
  • Resources
    • COVID-19 Resources for Cancer Survivors
    • Survivorship Checklist
    • Cancer Survival Toolbox
    • Telehealth
    • Survivorship Champions
    • Publications
      • Talking With Your Doctor
      • Self Advocacy
      • Employment Rights
      • Remaining Hopeful
    • Cancer Convos Podcast
    • Taking Charge of Your Care
    • Care Planning for Cancer Survivors
    • Tools For Care Providers
    • Order Our Resources
  • News
  • Events
    • Ellen L. Stovall Award
      • Nominations
      • Honorees
      • Sponsors
      • Committees
    • From Shadows to Life: A Biography of the Cancer Survivorship Movement
    • Cancer Policy Roundtable
      • Spring 2021 Cancer Policy Roundtable
      • Fall 2020 Cancer Policy Roundtable
      • Spring 2020 Cancer Policy Roundtable
    • Cancer Policy and Advocacy Team (CPAT) Symposium 2020
    • Webinars
  • Contact Us
  • Search
  • Menu Menu
  • 0Shopping Cart

Year-End MATCH (DEADLINE Dec 31): Donate & Make a Difference | Donate

20years

Guest Post by Amy Abernethy of Flatiron Health: Long-Term Medical Data Collection Improves Care Quality, Outcomes

August 27, 2015/in Cancer News, Cancer Policy Blog Care Planning, Quality Cancer Care NCCS News /by actualize
The eighth principle in the Imperatives for Quality Cancer Care states, “Systematic long-term follow-up should generate data that contribute to improvements in cancer therapies and decreases in morbidity.” In this post, Dr. Amy Abernethy addresses promising advances in the long-term collection of medical data, which could ultimately help medical professionals better understand what treatments are right for individual patients.

Amy Abernethy, MD, PhD

Guest Post By Amy Abernethy, MD, PhD
Chief Medical Officer & Senior Vice President, Flatiron Health

I once had a patient named Janet. Janet was a curly redhead emergency department nurse. She was vibrant, sweet, and vivacious, had melanoma, and was passionate about her data (her “story” as she liked to call it) being used in ways that would impact the future of cancer care. But this isn’t as easy as it might seem.

Janet wanted her story to be immortalized through research. As a nurse, she knew that clinical research and evidence development were fundamental to developing new treatments, and to getting them disseminated. She was mystified to find how hard this really was in the real world–that the data typed into the electronic health record (EHR) was really intended to support research, and that investigators and healthcare organizations were more focused on maintaining data rights to box out the competitor than contributing to a global good. Janet’s story was inaccessible to support her intentions.

Janet reminded me: While it’s critical that we work to obtain robust data to ensure that cancer patients receive the right treatment at the right time, there are key ingredients that are needed in order to make this happen. The first is that we need to have a large enough dataset in order to be able to draw statistically significant conclusions. In addition, the data needs to be longitudinal, so that we can capture complete information that allows us to see the full picture of what happened to each patient–from beginning to end. And, as Janet pointed out, it needs to be easy, comfortable, and controllable for patients to provide their data in a meaningful way.

“We are now able to use these data in ways that were impossible just a decade ago. Large scale outcomes analyses can help us understand the relationship between treatment sequence and mortality;
should a person with metastatic melanoma receive treatments A then B then C, or B then A then C?”
In addition to amassing a large amount of longitudinal data, we also need to ensure that this data is transferred into a common format that is analyzable and ready for use. Even the most seemingly consistent data types like laboratory tests and demographics are inconsistently collected. Often referred to as “structured data”, these data types must be transferred into a single format–a painstaking task even under the best of circumstances. But the rich information is in the hard-to-reach corners of the medical story: the “unstructured data”. This includes written medical case notes (akin to clinical stories), pdf documents (akin to image files), and important “others”, such as the scanned condolence card. These data types are fundamental in telling Janet’s story through data. However, clinicians talk about aspects of care differently based on their training, practice environment, and personal preferences. In order to compensate, we need to be prepared to invest in the hard work of culling the unstructured documents for key pieces of information that are critical to understanding a patient’s story. Current technology is not yet intelligent enough to completely automate this process, so it is quite laborious to fully abstract, analyze and interpret this unstructured data. Nonetheless, it is paramount to telling Janet’s story.

The amazing part is that Janet’s vision is happening. Her longitudinal story is being immortalized through data. Structured plus unstructured data processing, in a manner like what we are doing at Flatiron Health, is starting to turn her interrupted story into a full tale. Data sharing across the whole Flatiron Health network, soon to represent 20% of cancer patients in the US, is leading to the amalgamation of many many stories of Janets, Joes, Jennifers, and Javiers. Connecting in other datasets, like mortality, insurance claims, genomics, and patient reported outcomes helps to round out the stories.

What is next? We are now able to use these data in ways that were impossible just a decade ago. Large scale outcomes analyses can help us understand the relationship between treatment sequence and mortality; should a person with metastatic melanoma receive treatments A then B then C, or B then A then C? We can better understand the interplay between choice of treatment sequence and side effects. We’re able to deliver just-in-time information to providers about their selected treatments, including patient education materials and financial assistance programs, to ensure that both patients and providers are adequately prepared. We’re able to compare “like” patients over time, and look for emerging patterns in response to various treatments, furthering research and development of effective drugs. Ultimately, providers will be able to query the data set for patients similar to the one that is sitting in front of them. They could then identify the most effective line of therapy based on specific characteristics–which will bring down cost, improve quality of life for cancer patients, and ultimately make cancer a manageable disease with evidence-based treatments for every patient.

Janet wanted to donate her data for the benefit of future cancer patients in a way that was meaningful. In order to get there, we all have to work together–patients, providers, payers, pharma, regulatory agencies–to collaborate in the name of improved cancer care. We need to jointly identify a trusted, common data set that can be used for this purpose, and ensure that it is reliable, accurate, and available when needed. We need to work for Janet, so that even though Janet is no longer here, her legacy can live on through her data, ensuring that future patients are able to get the right treatment at the right time.


About the Author:
Amy Abernethy is the Chief Medical Officer and SVP of Oncology at Flatiron Health. Before joining Flatiron, Amy was Professor of Medicine at Duke University, and ran the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute. For more than a decade, she has pioneered the development of technology platforms to spur novel advancements in cancer care, including the development of systems by which big data can support personalized medicine and scientific discovery.

About Flatiron Health:
Flatiron Health helps the oncology community deliver better, more efficient care by powering an innovative platform to address today’s healthcare challenges. The Flatiron Health OncologyCloud™ platform includes the industry-leading electronic medical record for oncology, advanced analytics, patient portal, and integrated billing management. Backed by Google Ventures, First Round Capital, LabCorp and others, Flatiron’s industry-first technology platform and integrated suite of products deliver comprehensive support for cancer care providers and life science companies.
 
The views & opinions expressed in any guest post featured on our site are those of the guest author and do not necessarily reflect the opinions & views of the National Coalition for Cancer Survivorship.
Read our blog and comment policies here.


Tags: 20 Years Later, cancer care, Cancer Survivorship, care planning, data collection, Guest Post, quality
Share this entry
  • Share on Facebook
  • Share on Twitter
https://canceradvocacy.org/wp-content/uploads/2015/01/20years.gif 500 500 actualize https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png actualize2015-08-27 12:45:472015-08-27 12:45:47Guest Post by Amy Abernethy of Flatiron Health: Long-Term Medical Data Collection Improves Care Quality, Outcomes
You might also like
NCCS Starburst 250px Health Care Roundup: New Medicare Drug Pricing Proposal; New ACA Waiver Guidance; High Price of Precision Medicine; Midterms; More
NCCS Starburst 250px What Caught Our Eye 8/4: GOP Governors Look to Cut Medicaid, Young Cancer Survivors Struggle Socially, Right to Try, FDA Funding, & More
FacebookProfile3 NCCS adds care planning to Teamwork resource
Dome Thumbnail starburst NCCS Policy Comments: Recommending Cancer Survivorship as a Topic for FDA Patient-Focused Drug Development Meetings
Ben Fishman Poor Amendments Cannot Fix A Bad Bill
NCCS Starburst 250px What Caught Our Eye: ACA Open Enrollment Info, Tax Bill Eliminates Medical Expense Deduction, A Young Med Student’s Lymphoma Story
Zanartu Help Hurt Tool Physician Guest Blog: Example of a Case Impacted by the Help-Hurt Tool
the Institute of Medicine IOM Report Released Today, “Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis”

Latest News

NCCS Founders at 1990 Assembly

The Birth of the Cancer Survivorship Movement and How It Transformed Cancer Care for Millions

March 25, 2021
Guest Post by Judith L. Pearson Best-Selling Author of From Shadows to Life: A Biography…
Read more
https://canceradvocacy.org/wp-content/uploads/2018/02/10-Founders-1990-NCCS-Assembly.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2021-03-25 10:36:202021-03-25 13:46:05The Birth of the Cancer Survivorship Movement and How It Transformed Cancer Care for Millions
HHS Humphrey bldg 1200

Biden Rescinds Trump Admin Proposal to Limit Medicare Part D Coverage of Drugs in “Six Protected Classes”

March 19, 2021
This week, the Biden administration rescinded a Trump administration-proposed plan…
Read more
https://canceradvocacy.org/wp-content/uploads/2017/10/HHS-Humphrey-bldg-1200.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2021-03-19 13:36:192021-03-23 14:46:18Biden Rescinds Trump Admin Proposal to Limit Medicare Part D Coverage of Drugs in “Six Protected Classes”
CDC Headquarters

NCCS Recommends That States Allocate COVID-19 Vaccines to Cancer Care Providers

March 1, 2021
The National Coalition for Cancer Survivorship (NCCS) and the Cancer Leadership Council…
Read more
https://canceradvocacy.org/wp-content/uploads/CDC_Headquarters_PHIL_pubdomain_1200.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2021-03-01 15:49:432021-03-04 17:45:07NCCS Recommends That States Allocate COVID-19 Vaccines to Cancer Care Providers

Take Action

Stovall Award

The Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care is a unique opportunity for patients and survivors to recognize pioneers who are transforming the cancer care system.

Join CPAT

The NCCS Cancer Policy & Advocacy Team (CPAT) is a program for survivors and caregivers to learn about pressing policy issues that affect quality cancer care in order to be engaged as advocates in public policy around the needs of cancer survivors.

Share Your Story

NCCS represents the millions of Americans who share a common experience – the survivorship experience – living with, through and beyond a cancer diagnosis.

STAY CONNECTED

Together we can improve cancer care for survivors! Sign up to be the first to know about cancer policy issues and ways to take action

  • About
    • Our Mission
    • Our History
    • Our Leadership
      • Policy Advisors
    • Employment
    • Partnerships
    • Financial Information
  • Policy
    • Quality Cancer Care
    • Access to Care
    • Health Equity
    • Redefining Functional Status (RFS)
    • 2020 State of Cancer Survivorship Survey
    • Cancer Care Planning and Communications Act (CCPCA)
  • Get Involved
    • What is Advocacy?
    • Cancer Policy and Advocacy Team (CPAT)
    • Elevating Survivorship
    • Survivor Stories
    • Cancerversary
    • State Based Cancer Advocacy
  • Resources
    • COVID-19 Resources for Cancer Survivors
    • Survivorship Checklist
    • Cancer Survival Toolbox
    • Telehealth
    • Survivorship Champions
    • Publications
      • Talking With Your Doctor
      • Self Advocacy
      • Employment Rights
      • Remaining Hopeful
    • Cancer Convos Podcast
    • Taking Charge of Your Care
    • Care Planning for Cancer Survivors
    • Tools For Care Providers
    • Order Our Resources
  • News
  • Events
    • Ellen L. Stovall Award
      • Nominations
      • Honorees
      • Sponsors
      • Committees
    • From Shadows to Life: A Biography of the Cancer Survivorship Movement
    • Cancer Policy Roundtable
      • Spring 2021 Cancer Policy Roundtable
      • Fall 2020 Cancer Policy Roundtable
      • Spring 2020 Cancer Policy Roundtable
    • Cancer Policy and Advocacy Team (CPAT) Symposium 2020
    • Webinars
  • Contact Us

National Coalition for Cancer Survivorship
8455 Colesville Road  |  Suite 930  |  Silver Spring, MD 20910
877-NCCS-YES  |  info@canceradvocacy.org
Privacy Policy  |  Terms and Conditions

Copyright © 1995-2021 by the National Coalition for Cancer Survivorship
National Coalition for Cancer Survivorship, NCCS, Cancer Survival Toolbox, and related Logos are registered in the United States as trademarks of the National Coalition for Cancer Survivorship.

NCCS Responds to Draft ASCO Conceptual Framework to Assess the Value of Cancer... Fotolia 23428619 S e1461260836640 NCCS Starburst Thumbnail WCOE: Poll Finds Women Think Mammograms Should Be Done Annually, Why Your Doctor...
Scroll to top

Harmar Brereton, MD

Founder
Northeast Regional Cancer Institute

 

“Perhaps one of the most impactful collaborations in Dr. Brereton’s extraordinary career remains his early work and long friendship with Ellen Stovall. Through him, and in turn through the thousands of lives he has touched, Ellen’s work continues, and her mission lives on.”

—Karen M. Saunders
President, Northeast Regional Cancer Institute